-
Shocks and strategy shifts: Pharma and healthcare procurement in 2026
Insight
Explore the key 2026 trends reshaping pharma and healthcare procurement—from geopolitical shocks to AI, patent cliffs, and risi…
-
What’s ahead for procurement leaders in 2026
Insight
Discover key 2026 procurement and supply chain trends across sectors. Learn how leaders can boost resilience, leverage data and…
-
Making collaboration count: Unlocking procurement value across three NHS trusts
Case Study
HNYPC partnered with Efficio and AdviseInc, combining healthcare-specific spend analytics with deep procurement expertise. The …
-
US tariff updates & impact on key industries
Research updates
How are evolving US tariff measures impacting global supply chains, and what strategies can businesses adopt to stay resilient …
- Date
- 8 Oct 2025
-
Emerging biopharma’s critical lever for growth and valuation: Procurement
Insight
The article shares how emerging biopharma C-suite leaders can leverage procurement to unlock capital efficiency, de-risk operat…
-
Transforming global procurement: Innovating digital solutions and partnership
Case Study
Find out how a global corporation blended digital innovation with a partnership-led approach to transform its procurement funct…
-
Two transformations, one competitive edge: Procurement in Physician Practice Management
Case Study
A strategic approach to procurement helps Physician Practice Management companies to balance centralized operations with flexib…
-
How the Inflation Reduction Act is shaping pharma procurement strategies
Insight
The Inflation Reduction Act is rapidly altering how pharmaceutical companies think about costs, investment, and innovation – an…
-
Achieving sustainability targets via supply chains: The critical role of supplier engagement
Insight
Discover how a Sustainability Supplier Engagement program can help organizations across industries reduce carbon emissions and …
-
How can procurement create value in Pharma M&A?
Insight
Procurement is an often-underestimated area of opportunity in pharma mergers, acquisitions, and carve-outs – yet it has the pot…